Claims for Patent: 6,582,385
✉ Email this page to a colleague
Summary for Patent: 6,582,385
Title: | Hemofiltration system including ultrafiltrate purification and re-infusion system |
Abstract: | A hemofiltration system is provided in which ultrafiltrate is purified by reverse osmosis for reinfusion. Non-sterile infusate concentrate is dialyzed into the purified ultrafiltrate and combined with cleared blood which is returned to the patient. In another system, a hemofilter is used to sterilize essentially pure, non-sterile water for dilution of sterile infusate concentrate, then the hemofilter is used to filter blood, the infusate concentrate being combined with cleared blood for return to the patient. |
Inventor(s): | Burbank; Jeffrey H (Boxford, MA), Finch; C David (Clinton, MS), Brugger; James M (Newburyport, MA) |
Assignee: | NStage Medical, Inc. (Lawrence, MA) |
Application Number: | 09/027,301 |
Patent Claims: | 1. A system for processing blood from an individual comprising a draw path coupled to the individual to convey blood from the individual, a blood treatment unit communicating
with the draw path comprising a hemofiltration membrane operating to remove waste fluid comprising water and at least one ionic species from the blood, a waste outlet operating to convey the waste fluid from the blood treatment unit, and a treated blood
outlet operating to convey treated blood from the blood treatment unit following removal of the waste fluid, a non-sterile source of at least one replacement ionic species, a replacement fluid generation assembly comprising a waste treatment unit coupled
to the waste outlet operating to remove ionic species from the waste fluid to create essentially pure sterile water, and a pure water outlet operating to convey the essentially pure sterile water from the waste treatment unit, and a replenishment unit
coupled to the pure water outlet and the non-sterile source and including a semipermeable membrane to convey by ionic transport the at least one replacement ionic species from the non-sterile source into the essentially pure sterile water to form an
essential sterile replacement fluid, and a replacement fluid outlet operating to convey the essentially sterile replacement fluid from the replenishment unit, and a return path coupled to the individual and communicating with the treated blood outlet and
the replenishment fluid outlet to convey treated blood and the essentially sterile replacement fluid to the individual.
2. A system for processing blood from an individual comprising a draw path coupled to the individual to convey blood from the individual, a blood treatment unit communicating with the draw path comprising a hemofiltration membrane operating to remove waste fluid comprising water and at least one ionic species from the blood, a waste outlet operating to convey the waste fluid from the blood treatment unit, and a treated blood outlet operating to convey treated blood from the blood treatment unit following removal of the waste fluid, a sterile source of at least one replacement ionic species, a replacement fluid generation assembly comprising a waste treatment unit coupled to the waste outlet operating to remove ionic species from the waste fluid to create essentially pure sterile water, and a pure water outlet operating to convey the essentially pure sterile water from the waste treatment unit, and a replenishment unit coupled to the pure water outlet and the sterile source and including a semipermeable membrane to convey by ionic transport the at least one replacement ionic species from the sterile source into the essentially pure sterile water to form an essential sterile replacement fluid, and a replacement fluid outlet operating to convey the essentially sterile replacement fluid from the replenishment unit, and a return path coupled to the individual and communicating with the treated blood outlet and the replenishment fluid outlet to convey treated blood and the essentially sterile replacement fluid to the individual. 3. A system according to claim 1 or 2 wherein the waste treatment unit includes a reverse osmosis membrane. |
Details for Patent 6,582,385
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | 05/25/2006 | ⤷ Try a Trial | 2039-09-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.